Treatment of facial cutaneous carcinoma with high–dose rate contact brachytherapy with customized molds

Maroñas, M.; Guinot, José Luis; Arribas, L.; Carrascosa, M.; Tortajada, M.I.; Carmona, Ruth; Estornell, Marian; Muelas, R.

doi:10.1016/j.brachy.2010.08.005

Cited by 35 publications

(37 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In fact, during HDR-BT, the dose remains on the surface and does not penetrate deeply with optimal sparing of normal tissues due to dose concentration into the clinical target volumes (CTV) and rapid dose fall-off at target periphery [10, 11, 12, 13, 14, 15, 16, 17]. Published studies have mainly reported standard fractionation and hypofractionated brachytherapy regimens in patients treated with HDR-BT, and the biological effective dose (BED) was often calculated due to define the total dose and dose for fractions regimen for a better local control and acceptable late and acute toxicity [19, 20, 21, 22, 23, 24, 25, 26, 33, 34, 35, 36, 37]. …”

Section: Resultsmentioning

confidence: 99%

“…The development of new devices for small skin tumor treatment and the introduction of commercial electronic BT have attracted considerable interest for BT as a skin cancer treatment. Despite the new technologies available, few studies have focused on the treatment of NMSC with HDR-BT and hypofractionated regimes seems to be a valid option for the treatment of NMSC with very good local control, toxicity, and cosmetic result [19, 20, 21, 22, 23, 24, 25, 26, 32, 33, 34, 35, 36, 37, 43, 44]. In 1999, Köhler-Brock et al .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Non-melanoma skin cancer treated with high-dose-rate brachytherapy: a review of literature

Delishaj¹,

Rembielak²,

Manfredi³

et al. 2016

jcb

View full text Add to dashboard Cite

PurposeThe incidence of non-melanoma skin cancer (NMSC) has been increasing over the past 30 years. There are different treatment options and surgical excision is the most frequent treatment due to its low rates of recurrence. Radiotherapy is an effective alternative of surgery, and brachytherapy (BT) might be a better therapeutic option due to high radiation dose concentration to the tumor with rapid dose fall-off resulting in normal tissues sparing. The aim of this review was to evaluate the local control, toxicity, and cosmetic outcomes in NMSC treated with high-dose-rate BT (HDR-BT).Material and methodsIn May 2016, a systematic search of bibliographic database of PubMed, Web of Science, Scopus, and Cochrane Library with a combination of key words of “skin cancer”, “high dose rate brachytherapy”, “squamous cell carcinoma”, “basal cell carcinoma”, and “non melanoma skin cancer“ was performed. In this systematic review, we included randomized trials, non-randomized trials, prospective and retrospective studies in patients affected by NMSC treated with HDR-BT.ResultsOur searches generated a total of 85 results, and through a process of screening, 10 publications were selected for the review. Brachytherapy was well tolerated with acceptable toxicity and high local control rates (median: 97%). Cosmetic outcome was reported in seven study and consisted in an excellent and good cosmetic results in 94.8% of cases.ConclusionsBased on the review data, we can conclude that the treatment of NMSC with HDR-BT is effective with excellent and good cosmetics results, even in elderly patients. The hypofractionated course appears effective with very good local disease control. More data with large-scale randomized controlled trials are needed to assess the efficacy and safety of brachytherapy.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Non-melanoma skin cancer treated with high-dose-rate brachytherapy: a review of literature

Delishaj¹,

Rembielak²,

Manfredi³

et al. 2016

jcb

View full text Add to dashboard Cite

show abstract

“…No other late toxicities were reported in this study [52]. In a study of hypofractionated HDR brachytherapy (48-57 Gy in 12-19 fractions) for NMSC of the face, Maronas et al found that no patients developed late toxicity and all patients had good or very good cosmesis [60]. Late toxicity with EBT also appeared to be low.…”

Section: Hdr Brachytherapymentioning

confidence: 70%

Radiotherapy treatment for nonmelanoma skin cancer

Rong

Zuo

Shang

et al. 2015

Expert Review of Anticancer Therapy

View full text Add to dashboard Cite

Non-melanoma skin cancer is the most common malignancy in the USA, with an estimated 3.5 million cases per year. Treatment options include surgical excision, radiation therapy (RT), photodynamic therapy and topical agents. Although surgical excision remains the mainstay of therapy, RT offers an effective alternative. RT can be used as an adjunct to surgery in high-risk situations, or in cases where surgical excision would lead to impaired cosmesis and/or functional outcomes. Radiation treatment modalities for non-melanoma skin cancers are diverse. Studies in the literature have examined the clinical effects of a wide variety of modalities, areas of the body and dosages. The most common modalities include superficial or orthovoltage RT, electron beam therapy and high dose-rate brachytherapy. This article aims to review the diverse radiotherapy treatment modalities for non-melanoma skin cancers, focusing on tumor control and toxicity.

show abstract

“…However, there are only few reports of outcome with SMB using HDR brachytherapy, and have been summarized in Table 4. Amongst the published data, majority of the studies have focused on SMB for skin cancers [6,7,8,9]. In our study, there were 21 patients with intraoral tumours and 14 patients with skin malignancies.…”

Section: Discussionmentioning

confidence: 85%

“…High-dose-rate brachytherapy is now widely used in many parts of the world and has shown to have equivalent outcomes compared to other dose rates for some head and neck malignancies [5]. There have been few reports regarding the use of SMB in the HDR era for skin malignancies involving skin of face (including nose, pinna) resulting in outcomes comparable with other treatment strategies [6,7,8,9]. However, very limited literature is available for SMB for intra-oral malignancies and involved less number of patients [10,11,12].…”

Section: Purposementioning

confidence: 99%

Clinical outcomes with high-dose-rate surface mould brachytherapy for intra-oral and skin malignancies involving head and neck region

Budrukkar¹,

Dasgupta²,

Pandit³

et al. 2017

jcb

View full text Add to dashboard Cite

PurposeThe literature and experience of high-dose-rate (HDR) surface mould brachytherapy (SMB) in head and neck cancer is sparse. We report our institutional experience of SMB for such tumours.Material and methodsThirty-five patients with malignant localized early T1/T2, N0 (21 intra-oral and 14 skin) tumours treated with SMB during 2008-2014 were analyzed. Treatment was delivered using HDR 192Ir source to a median dose of 49 Gy (range, 38.5-52.5 Gy) as radical brachytherapy and 18 Gy (range, 15.5-30 Gy) as boost with 3-4 Gy/fraction twice daily using customized surface mould.ResultsMedian follow-up was 52 months (range, 6 to 98 months). Local control (LC) for skin tumours and intra-oral malignancies at 5 years were 92% and 76%, respectively. Five-year cause specific survival was 92%. For T1 and T2 tumours, 5 year LC was 94.2% and 68.2%, respectively. T stage (p < 0.04) and dose/fractions (p < 0.003) were the only significant prognostic factors for LC on univariate analysis.ConclusionsSurface mould brachytherapy results in excellent LC rates for skin tumours and T1 intraoral tumours when considered as radical treatment, and preferable to consider it as a boost for T2 intraoral tumours. Surface mould brachytherapy results in excellent organ and function preservation.

show abstract

Treatment of facial cutaneous carcinoma with high–dose rate contact brachytherapy with customized molds

Cited by 35 publications

References 19 publications

Non-melanoma skin cancer treated with high-dose-rate brachytherapy: a review of literature

Non-melanoma skin cancer treated with high-dose-rate brachytherapy: a review of literature

Radiotherapy treatment for nonmelanoma skin cancer

Clinical outcomes with high-dose-rate surface mould brachytherapy for intra-oral and skin malignancies involving head and neck region

Contact Info

Product

Resources

About